NCT00722384

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

An Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 by Single Intravitreal Injection in Patients With Wet Age-Related Macular Degeneration

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: OPKO Health, Inc. · Industry
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.

Conditions

• Macular Degeneration

Interventions

Type	Name	Description
DRUG	bevasiranib
DRUG	bevasiranib	The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.

Timeline

• Start date: 2004-08-01
• Primary completion: 2007-08-01
• Completion: 2007-12-01
• First posted: 2008-07-25
• Last updated: 2008-07-25

Locations

1 site across 1 country: United States